



BRIAN SANDOVAL  
Governor

STATE OF NEVADA  
DEPARTMENT OF HEALTH AND HUMAN SERVICES  
**DIVISION OF HEALTH CARE FINANCING AND POLICY**  
1100 E. William Street, Suite 101  
Carson City, Nevada 89701  
(775) 684-3600

ROMAINE GILLILAND  
Director

LAURIE SQUARTSOFF  
Administrator

**NOTICE OF PUBLIC MEETING – DRUG USE REVIEW BOARD**

**REVISED AGENDA**

**Date of Posting:** January 6, 2015

**Date of Meeting:** Thursday, January 22, 2015 at 5:30 PM

**Name of Organization:** The State of Nevada, Department of Health and Human Services, Division of Health Care Financing and Policy (DHCFP), Drug Use Review Board (DUR).

**Place of Meeting:** Silver Legacy  
Silver/Gold Room  
407 N Virginia St  
Reno, Nevada 89501

**AGENDA**

- 1. Call to Order and Roll Call**
- 2. Public Comment on Any Matter on the Agenda**
- 3. Administrative**
  - a. **For Possible Action:** Review and Approve Meeting Minutes from July 24, 2014.
  - b. Status Update by DHCFP
    - i. Public Comment
    - ii. Medicaid's overview of the upcoming legislative session
    - iii. Introduction of new member, Dr. Michael Owens.
- 4. Presentation and Discussion of Nevada's Prescription Monitoring Program**
  - a. Jenine M. Davis, Pre-Criminal Intervention Officer, Controlled Substance Abuse Prevention Task Force
- 5. Clinical Presentations**

- a. **For Possible Action:** Discussion and proposed adoption of updated clinical prior authorization criteria for sofosbuvir (Sovaldi®).
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by the Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
  
- b. **For Possible Action:** Discussion and proposed adoption of prior authorization criteria for Ledipasvir-Sofosbuvir (Harvoni®).
  - i. Public Comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by the Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria
  
- c. **For Possible Action:** Discussion and proposed adoption of updated clinical prior authorization criteria for simeprevir (Olysio®).
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
  
- d. **For Possible Action:** Discussion and proposed adoption of updated prior authorization criteria for Oxycodone w/acetaminophen tab CR (Xartemis XR®).
  - i. Public Comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by the Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
  
- e. **For Possible Action:** Discussion and proposed adoption of updated prior authorization criteria for apixaban (Eliquis®).
  - i. Public Comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by the Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
  
- f. **For Possible Action:** Discussion and proposed adoption of updated clinical prior authorization criteria for the immunomodulator class of medication.
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.

- iv. Proposed adoption of updated prior authorization criteria.
- g. **For Possible Action:** Discussion and proposed adoption of updated clinical prior authorization criteria for transdermal fentanyl.
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.
- h. **For Possible Action:** Discussion and proposed adoption of updated clinical prior authorization criteria for palivizumab (Synagis®).
  - i. Public comment on proposed clinical prior authorization criteria.
  - ii. Presentation of utilization and clinical information.
  - iii. Discussion by Board and review of utilization data.
  - iv. Proposed adoption of updated prior authorization criteria.

## 6. DUR Board Requested Reports

- a. Report on Top 10 Black Box warning medications:
  - i. Public comment on Black Box warnings.
  - ii. Discussion by the Board and review of utilization data.
- b. Report on controlled substance utilization and trends.
  - i. Public comment on controlled substance utilization and trends.
  - ii. Discussion by the Board and review of utilization data.
- c. Report on psychotropic drug use in children.
  - i. Public comment on psychotropic drug use in children.
  - ii. Discussion by the Board and review of utilization data.
- d. Report on buprenorphine and buprenorphine/naloxone use.
  - i. Public comment on buprenorphine and buprenorphine/naloxone use.
  - ii. Discussion by the Board and review of utilization data.
- e. Report on Nevada Medicaid Lock-in Program
  - i. Public comment on Lock-in Program.
  - ii. Discussion by the Board and review of utilization data.
- f. Report on Asthma treatment utilization.

- i. Public comment on asthma treatment utilization.
  - ii. Discussion by the Board and review of utilization data.
- g. Report on Tussionex Utilization.
- i. Public comment on Tussionex Utilization.
  - ii. Discussion by the Board and review of utilization data.

## **7. Standard DUR Reports**

- a. Review of Prescribing/Program Trends.
  - i. Top 10 Therapeutic Classes for Q2 2014, Q3 2014, and Q4 2014 (by Payment and by Claims).
  - ii. Top 50 Drugs of Q2 2014, Q3 2014, and Q4 2014 (by Payment and by Claims).
- b. Concurrent Drug Utilization Review (ProDUR)
  - i. Review of Q2 2014, Q3 2014, and Q4 2014.
  - ii. Review of Top Encounters by Problem Type.
- c. Retrospective Drug Utilization Review (RetroDUR)
  - i. Public comment on Retro DUR.
  - ii. Status of previous quarter.
  - iii. Status of current quarter.
  - iv. Review and discussion of responses.

## **8. Closing Discussion**

- a. Public comments on any subject.
- b. Date and location of the next meeting.
  - i. Discussion of the time of the next meeting.
- c. Adjournment.

**Nevada Medicaid is unaware of any financial impact to other entities or local government due to this public hearing, other than as stated above.**

**PLEASE NOTE: Items may be taken out of order at the discretion of the chairperson. Items may be combined for consideration by the public body. Items may be pulled or removed from the agenda at any time. If an action item is not completed within the time frame that has been allotted, that action item will be continued at a future time designated and**

announced at this meeting by the chairperson. All public comment may be limited to 5 minutes.

**This notice and agenda have been posted at [www.dhcfp.nv.gov](http://www.dhcfp.nv.gov) and <http://notice.nv.gov>**

---

**Notice of this meeting and draft copies of the changes will be available on or after the date of this notice at the DHC FP Web site [www.dhcfp.nv.gov](http://www.dhcfp.nv.gov), Carson City Central office and Las Vegas DHC FP. The agenda posting of this meeting can be viewed at the following locations: Nevada State Library; Carson City Library; Churchill County Library; Las Vegas Library; Douglas County Library; Elko County Library; Lincoln County Library; Lyon County Library; Mineral County Library; Tonopah Public Library; Pershing County Library; Goldfield Public Library; Eureka Branch Library; Humboldt County Library; Lander County Library; Storey County Library; Washoe County Library; and White Pine County Library and may be reviewed during normal business hours.**

**If requested in writing, a draft copy of the changes will be mailed to you. Requests and/or written comments on the proposed changes may be sent to the Rita Mackie at the Division of Health Care Financing and Policy, 1100 E. William Street, Suite 101, Carson City, NV 89701, at least 3 days before the public hearing.**

**All persons that have requested in writing to receive the Public Hearings agenda have been duly notified by mail or e-mail.**

**Note: We are pleased to make reasonable accommodations for members of the public who are physically challenged and wish to attend the meeting. If special arrangements for the meeting are necessary, please notify the Division of Health Care Financing and Policy, in writing, at 1100 East William Street, Suite 101, Carson City, Nevada 89701 or call Rita Mackie at (775) 684-3681, as soon as possible, or e-mail at [rmackie@dhcfp.nv.gov](mailto:rmackie@dhcfp.nv.gov)**